1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Chacón RD and Costanzo MV: Triple-negative
breast cancer. Breast Cancer Res. 12((Suppl) 2): S32010. View Article : Google Scholar :
|
3
|
Reddy KB: Triple-negative breast cancers:
An updated review on treatment options. Curr Oncol. 18:e173–e179.
2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Dawson SJ, Rueda OM, Aparicio S and Caldas
C: A new genome-driven integrated classification of breast cancer
and its implications. EMBO J. 32:617–628. 2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Relja B, Meder F, Wilhelm K, Henrich D,
Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces
apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int
J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Lee J, Lee I, Han B, Park JO, Jang J, Park
C and Kang WK: Effect of simvastatin on cetuximab resistance in
human colorectal cancer with KRAS mutations. J Natl Cancer Inst.
103:674–688. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Hoque A, Chen H and Xu XC: Statin induces
apoptosis and cell growth arrest in prostate cancer cells. Cancer
Epidemiol Biomarkers Prev. 17:88–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Favero GM, F Otuki M, Oliveira KA, Bohatch
MS Jr, Borelli P, Barros FE, Maria DA, Fernandes D and Bydlowski
SP: Simvastatin impairs murine melanoma growth. Lipids Health Dis.
9:1422010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Chan KK, Oza AM and Siu LL: The statins as
anticancer agents. Clin Cancer Res. 9:10–19. 2003.PubMed/NCBI
|
10
|
Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS,
Cai DQ, Wu Z, Qin JW, Yu YH and Kim SK: HMG-CoA reductase
inhibitors induce apoptosis of lymphoma cells by promoting ROS
generation and regulating Akt, Erk and p38 signals via suppression
of mevalonate pathway. Cell Death Dis. 4:e5182013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Ahern TP, Pedersen L, Tarp M,
Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT and Lash TL:
Statin prescriptions and breast cancer recurrence risk: A Danish
nationwide prospective cohort study. J Natl Cancer Inst.
103:1461–1468. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Graaf MR, Richel DJ, van Noorden CJ and
Guchelaar HJ: Effects of statins and farnesyltransferase inhibitors
on the development and progression of cancer. Cancer Treat Rev.
30:609–641. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Rohilla A, Rohilla S, Kumar A, Khan MU and
Deep A: Pleiotropic effects of statins: A boulevard to
cardioprotection. Arab J Chem. 9:S21–S27. 2016. View Article : Google Scholar
|
14
|
Gopalan A, Yu W, Sanders BG and Kline K:
Eliminating drug resistant breast cancer stem-like cells with
combination of simvastatin and gamma-tocotrienol. Cancer Lett.
328:285–296. 2013. View Article : Google Scholar
|
15
|
Fuchs D, Berges C, Opelz G, Daniel V and
Naujokat C: HMG-CoA reductase inhibitor simvastatin overcomes
bortezomib-induced apoptosis resistance by disrupting a
geranylgeranyl pyro-phosphate-dependent survival pathway. Biochem
Biophys Res Commun. 374:309–314. 2008. View Article : Google Scholar : PubMed/NCBI
|
16
|
Sadeghi-Aliabadi H, Minaiyan M and
Dabestan A: Cytotoxic evaluation of doxorubicin in combination with
simvastatin against human cancer cells. Res Pharm Sci. 5:127–133.
2010.PubMed/NCBI
|
17
|
Barancik M, Bohacova V, Gibalova L, Sedlak
J, Sulova Z and Breier A: Potentiation of anticancer drugs: Effects
of pentoxifylline on neoplastic cells. Int J Mol Sci. 13:369–382.
2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Słoczyńska K, Kózka M, Pękala E, Marchewka
A and Marona H: In vitro effect of pentoxifylline and lisofylline
on deformability and aggregation of red blood cells from healthy
subjects and patients with chronic venous disease. Acta Biochim
Pol. 60:129–135. 2013.
|
19
|
Goel PN and Gude RP: Delineating the
anti-metastatic potential of pentoxifylline in combination with
liposomal doxorubicin against breast cancer cells. Biomed
Pharmacother. 68:191–200. 2014. View Article : Google Scholar : PubMed/NCBI
|
20
|
Bravo-Cuellar A, Hernández-Flores G,
Lerma-Díaz JM, Domínguez-Rodríguez JR, Jave-Suárez LF, De
Célis-Carrillo R, Aguilar-Lemarroy A, Gómez-Lomeli P and
Ortiz-Lazareno PC: Pentoxifylline and the proteasome inhibitor
MG132 induce apoptosis in human leukemia U937 cells through a
decrease in the expression of Bcl-2 and Bcl-XL and phosphorylation
of p65. J Biomed Sci. 20:132013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Fan S, Smith ML, Rivet DJ II, Duba D, Zhan
Q, Kohn KW, Fornace AJ Jr and O'Connor PM: Disruption of p53
function sensitizes breast cancer MCF-7 cells to cisplatin and
pentoxifylline. Cancer Res. 55:1649–1654. 1995.PubMed/NCBI
|
22
|
Goel PN and Gude RP: Unravelling the
antimetastatic potential of pentoxifylline, a methylxanthine
derivative in human MDA-MB-231 breast cancer cells. Mol Cell
Biochem. 358:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
23
|
Kamran MZ and Gude RP: Preclinical
evaluation of the anti-metastatic efficacy of Pentoxifylline on
a375 human melanoma cell line. Biomed Pharmacother. 66:617–626.
2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Goel PN and Gude RP: Pentoxifylline
regulates the cellular adhesion and its allied receptors to
extracellular matrix components in breast cancer cells. Biomed
Pharmacother. 68:93–99. 2014. View Article : Google Scholar
|
25
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
26
|
Bhat UG, Pandit B and Gartel AL: ARC
synergizes with ABT-737 to induce apoptosis in human cancer cells.
Mol Cancer Ther. 9:1688–1696. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar
|
28
|
Brasier AR: The nuclear
factor-kappaB-interleukin-6 signalling pathway mediating vascular
inflammation. Cardiovasc Res. 86:211–218. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Viry E, Paggetti J, Baginska J,
Mgrditchian T, Berchem G, Moussay E and Janji B: Autophagy: An
adaptive metabolic response to stress shaping the antitumor
immunity. Biochem Pharmacol. 92:31–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan
G, Wang R and Kong D: ZSTK474, a specific class I
phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and
autophagy in human breast cancer MCF-7 cells. Oncotarget.
7:19897–19909. 2016.PubMed/NCBI
|
31
|
Giuliano S, Cormerais Y, Dufies M, Grépin
R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S,
Mazure NM, et al: Resistance to sunitinib in renal clear cell
carcinoma results from sequestration in lysosomes and inhibition of
the autophagic flux. Autophagy. 11:1891–1904. 2015. View Article : Google Scholar : PubMed/NCBI
|
32
|
Chu PM, Chen LH, Chen MT, Ma HI, Su TL,
Hsieh PC, Chien CS, Jiang BH, Chen YC, Lin YH, et al: Targeting
autophagy enhances BO-1051-induced apoptosis in human malignant
glioma cells. Cancer Chemother Pharmacol. 69:621–633. 2012.
View Article : Google Scholar
|
33
|
Tucci M, Stucci S, Savonarola A, Resta L,
Cives M, Rossi R and Silvestris F: An imbalance between Beclin-1
and p62 expression promotes the proliferation of myeloma cells
through autophagy regulation. Exp Hematol. 42:897–908. e8912014.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Cagnol S and Chambard JC: ERK and cell
death: Mechanisms of ERK-induced cell death - apoptosis, autophagy
and senescence. FEBS J. 277:2–21. 2010. View Article : Google Scholar
|
35
|
Sharma K, Ishaq M, Sharma G, Khan MA,
Dutta RK and Majumdar S: Pentoxifylline triggers autophagy via ER
stress response that interferes with Pentoxifylline induced
apoptosis in human melanoma cells. Biochem Pharmacol. 103:17–28.
2016. View Article : Google Scholar : PubMed/NCBI
|
36
|
Wang T, Seah S, Loh X, Chan CW, Hartman M,
Goh BC and Lee SC: Simvastatin-induced breast cancer cell death and
deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by
metabolic products of the mevalonate pathway. Oncotarget.
7:2532–2544. 2016.
|
37
|
Palanivel K, Kanimozhi V, Kadalmani B and
Akbarsha MA: Verrucarin A induces apoptosis through ROS-mediated
EGFR/MAPK/Akt signaling pathways in MDA-MB-231 breast cancer cells.
J Cell Biochem. 115:2022–2032. 2014.PubMed/NCBI
|
38
|
Zhang S, He Y, Tong Q, Chen Q, Wu X and
Huang W: Deltonin induces apoptosis in MDA-MB-231 human breast
cancer cells via reactive oxygen species-mediated mitochondrial
dysfunction and ERK/AKT signaling pathways. Mol Med Rep.
7:1038–1044. 2013. View Article : Google Scholar : PubMed/NCBI
|
39
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
40
|
Pathania AS, Kumar S, Guru SK, Bhushan S,
Sharma PR, Aithagani SK, Singh PP, Vishwakarma RA, Kumar A and
Malik F: The synthetic tryptanthrin analogue suppresses STAT3
signaling and induces caspase dependent apoptosis via ERK up
regulation in human leukemia HL-60 cells. PLoS One. 9:e1104112014.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Singh S, Upadhyay AK, Ajay AK and Bhat MK:
p53 regulates ERK activation in carboplatin induced apoptosis in
cervical carcinoma: A novel target of p53 in apoptosis. FEBS Lett.
581:289–295. 2007. View Article : Google Scholar : PubMed/NCBI
|
42
|
Pettersson F, Couture MC, Hanna N and
Miller WH: Enhanced retinoid-induced apoptosis of MDA-MB-231 breast
cancer cells by PKC inhibitors involves activation of ERK.
Oncogene. 23:7053–7066. 2004. View Article : Google Scholar : PubMed/NCBI
|
43
|
Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung
Y, Komarov AP, Keyomarsi K, Yarden Y and Seger R: Taxol-induced
apoptosis depends on MAP kinase pathways (ERK and p38) and is
independent of p53. Oncogene. 20:147–155. 2001. View Article : Google Scholar : PubMed/NCBI
|
44
|
Landskron G, De La Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu
Y, Gong Z, Zhang S, Zhou J, Cao K, et al: Role of tumor
microenvironment in tumorigenesis. J Cancer. 8:761–773. 2017.
View Article : Google Scholar : PubMed/NCBI
|